Sacramento Bee1d
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Non-Habit Forming: Unlike Pregabalin, Ketamir-2 carries no known risk of dependence, making it safer for long-term use. Fewer ...
MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments
MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...
Zacks Small Cap Research on MSN18h
MIRA Continues to Post Outstanding Test Results
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
Miami Herald1mon
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Neuropathic pain is a complex and debilitating condition caused by a variety of causes, induced by damage or dysfunction of the nervous system. It often presents as burning, electric shocks, or ...
Benzinga.com24d
Why Mira Shares Are Trading Higher Today
MIRA shares surge 10.3% after new preclinical data shows Ketamir-2 achieves 100% reversal of neuropathic pain. Ketamir-2 presentation set for October's Pain Therapeutics Summit, highlighting its ...
WREG1mon
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Ketamir-2 is MIRA's response to this pressing market need-a novel ketamine analog designed to enhance therapeutic efficacy, improve oral bioavailability, and offer a superior safety profile ...